Parker, Christopher C <br/><br/>
Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial.  [electronic resource] 

 -  Lancet (London, England)  12 2018 
 - 2353-2366 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1474-547X 
<br/><br/><label>Standard No.: </label>10.1016/S0140-6736(18)32486-3  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Aged<br/>Antineoplastic Agents--therapeutic use<br/>Disease-Free Survival<br/>Docetaxel--therapeutic use<br/>Gonadotropin-Releasing Hormone--agonists<br/>Humans<br/>Lymph Nodes--pathology<br/>Male<br/>Middle Aged<br/>Neoplasm Metastasis<br/>Orchiectomy<br/>Prostatic Neoplasms--drug therapy<br/>Radiotherapy--adverse effects<br/>Standard of Care<br/>Survival Analysis<br/>Treatment Outcome